Table 2. CA15-3 levels with different assays depending on the best response to the chemotherapy treatment.
| n | Baseline Median CA15-3, U/mL (IQR) |
Week 6 Median CA15-3 U/mL (IQR) |
Change, median % (IQR)a | pb | Declining CA15-3 levels, n (%)c | Increase in CA15-3 levels, n (%)d | |
|---|---|---|---|---|---|---|---|
| Conventional CA15-3 | |||||||
| PR | 25 | 71.1 (29.4–228) | 55.4 (28.8–103) | -23.8 [-52.7-(-14.0)] | 0.003 | 10 (40.0) | 2 (8.0) |
| SD | 14 | 19.2 (12.6–81.4) | 25.8 (14.9–71.0) | -0.4 (-37.1–60.5) | 0.875 | 4 (28.6) | 5 (35.7) |
| PD | 2 | 24.1 (15.0–33.1) | 29.2 (17.5–40.9) | +20.1 (16.7–23.6) | 0.180 | 0 | 0 |
| CA15-3MGL | |||||||
| PR | 25 | 6.3 (2.1–45.1) | 2.4 (0.9–4.8) | -75.0 [-86.4-(-41.0)] | <0.001 | 18 (78.2) | 3 (13.0) |
| SD | 14 | 3.2 (1.0–5.4) | 2.2 (0.8–3.6) | -33.3 (-67.0–33.3) | 0.036 | 7 (53.8) | 4 (30.7) |
| PD | 2 | 4.1 (3.2–5.0) | 3.0 (2.2–3.9) | -17.0 (-56.0–21.9) | 0.655 | 1 (50.0) | 0 |
| CA15-3WGA | |||||||
| PR | 25 | 13.2 (5.3–76.5) | 8.0 (3.5–33.2) | -27.2 [-55.9-(-19.4)] | <0.001 | 12 (48.0) | 2 (8.0) |
| SD | 14 | 3.2 (2.4–8.7) | 5.0 (2.7–8.2) | +22.2 (-25.4–60.0) | 0.851 | 3 (21.4) | 7 (50.0) |
| PD | 2 | 4.7 (2.3–7.0) | 5.8 (2.3–9.3) | +16.4 (0–32.9) | 0.317 | 0 | 1 (50.0) |
Abbreviations: n = number of patients, CI = confidence interval, PR = partial response, SD = stable disease, PD = progressive disease
a Change in CA15-3 levels from baseline to week six in percentiles, median
b Wilcoxon Rank Test
c Patients with ≥ 30% decline in CA15-3 levels from baseline to week six
d Patients with ≥ 30% increase in CA15-3 levels from baseline to week six